Navigation Links
FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
Date:3/21/2011

BOSTON, March 21, 2011 /PRNewswire/ -- Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's recently submitted Investigational New Drug (IND) application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.  ARI-3037MO, a proprietary new chemical entity, is a once-daily, niacin analog being developed for the treatment of dyslipidemia. In preclinical pharmacology studies, the compound produced greater lipid responses than niacin in a relevant animal model of hyperlipidemia.  Additionally, ARI-3037MO showed an extremely favorable safety profile, including the absence of flushing, in non-clinical drug safety studies. The Company believes that an efficacious and well tolerated niacin analog will be more widely utilized than existing forms of niacin in treating hypercholesterolemia, a disorder that afflicts as many as 93 million Americans according to data published by the American Heart Association.(1)

(Logo: http://photos.prnewswire.com/prnh/20110321/NE69091LOGO)

"The FDA's acceptance of our IND is a major milestone for Arisaph, particularly considering that we developed the compound from lead selection to IND filing in about 9 months," said Christopher P. Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals.  "With ARI-3037MO, we have designed a once a day, structural analog of niacin that retains niacin's beneficial biological effects on lipids without producing the irritating side effect of flushing."    

As part of the IND submission, Arisaph completed comprehensive nonclinical drug safety studies, including 28-day toxicology studies in rats and dogs.  The results show that ARI-3037MO has a favorable safety pharmacology profile and a wide therapeutic index.  One of the major challenges with current forms of niacin is that they are d
'/>"/>

SOURCE Arisaph Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NYSE Amex Accepts China Shenghuos Compliance Plan for Continued Listing
2. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
3. The SCOOTER Store Accepts Medicare Contracts
4. FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review
5. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
6. FDA Accepts Sanofi Pasteurs Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
7. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
8. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
9. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
10. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
11. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014   Plexus ... provider of Anesthesia Information Management Systems (AIMS), announced ... LLC , a wholly owned subsidiary of Quality ... information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership extends ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it recently received ... Dr. Ricardo Garcia-Rivera , Founder and Chief Medical ... our quality of service has been recognized by The ... and continuity of care to patients of our expanding ... States ." NeuroCall currently provides ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... The Leukemia & Lymphoma,Society has awarded a $550,000 grant ... Cancer Center at the University of Rochester Medical,Center. Millennium ... the first two years of the five-year program., ... support,Dr. Friedberg,s work on a new targeted treatment for ...
... Medivation, Inc.,(Nasdaq: MDVN ) today announced that ... on Monday, July 7, to discuss top-line results ... of,dimebon(TM) in Huntington,s disease., Teleconference/Webcast Details, ... July 7, at 5:00 p.m. Eastern,time by telephone, ...
Cached Medicine Technology:University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society 2Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease 2
(Date:10/2/2014)... WEDNESDAY, Oct. 1, 2014 (HealthDay News) -- Genes may interact ... new study suggests. The genetic risk occurs in about ... white. The finding could help these people reduce their heart ... healthy diet and stress management, the Duke University researchers said. ... people and found a strong link between variations in the ...
(Date:10/2/2014)... Thompson HealthDay Reporter ... pull out all the stops to rescue surgical patients ... the cost of such heroism is questionable, a new ... percent better at saving elderly patients with life-threatening complications ... less intensity, said senior author Dr. Amir Ghaferi. He ...
(Date:10/1/2014)... An international team of scientists has shown that more ... treated with existing drugs. , The study found that ... cancers with a genetic mutation that is present in ... JAK inhibitors are currently used, or are in clinical ... and myeloproliferative disorders. , Bowel cancer is the second-most ...
(Date:10/1/2014)... policy focus on expanding access to care for ... to have significant dental disease. In this month,s ... Dental Association , researchers from Tufts University School ... Medicine report on the first large-scale survey to ... caregivers to adults with developmental disabilities. The study ...
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... issues in war-torn African countries are subjects close to ... of nursing at the University of WisconsinMilwaukee (UWM) who ... on improving health care delivery in war-torn African countries. ... African Countries," is a case study of Buseh,s home ...
... 22 /PRNewswire/ -- Stern ... just helped launch its new client www.healthcarebluebook.com ... fair prices in their zip code for healthcare ... and science information into strategic communications resources and ...
... than $3.0 BillionSYDNEY, Australia and BEDMINSTER, N.J., Jan. 22 ... QRXPY), a clinical-stage specialty pharmaceutical company focused on the ... nervous system (CNS) disorders, announced today that Jesus Soriano, ... Dr. Soriano brings more than 17 years of experience ...
... key role in helping new mothers to share experiences and ... of the UK-based Journal of Advanced Nursing . , ... Assistant Professor Valerie Irvine from the University of Victoria, Canada, ... who had all given birth in the same year and ...
... Online Resource Emphasizes Safety Products and Support ServicesBETHLEHEM, ... Braun) has launched a new Web site exclusively ... for home infusion therapy (HIT).(LOGO: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ... a fast and easy way for home healthcare ...
... Health Partnership - It,s In Our Hands - Has ... Patients And Caregivers To Healthcare Resources And Services In ... initiation of its Community Health Partnership (CHP), It,s ... to link African American residents with local healthcare professionals ...
Cached Medicine News:Health News:Book examines heath care delivery in war-torn Africa 2Health News:Book examines heath care delivery in war-torn Africa 3Health News:Stern Communications Wins and Helps Launch Healthcarebluebook.com 2Health News:QRxPharma Expands Management Team with the Addition of Dr. Jesus Soriano as Executive Vice President 2Health News:QRxPharma Expands Management Team with the Addition of Dr. Jesus Soriano as Executive Vice President 3Health News:QRxPharma Expands Management Team with the Addition of Dr. Jesus Soriano as Executive Vice President 4Health News:Community-based Internet forums are great for new mothers, but could marginalize fathers 2Health News:Community-based Internet forums are great for new mothers, but could marginalize fathers 3Health News:B. Braun Medical Inc. Launches Home Infusion Therapy Web Site 2Health News:Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care 2Health News:Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care 3
Bravo Vacuum Pump Accessories Kit (One canister, one lid, one "O" ring tube, one tubing set)...
Bravo pH capsule with delivery system....
Buffer solution is needed to calibrate pH catheters. The specific chloride ion concentration in the Medtronic buffers is required for proper function of your Medtronic pH measurement system. Buffer s...
Buffer solution is needed to calibrate pH catheters. The specific chloride ion concentration in the Medtronic buffers is required for proper function of your Medtronic pH measurement system. Buffer s...
Medicine Products: